On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea in adult men and women. Read more.
FDA approves treatments for irritable bowel syndrome
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.
